Also from this source


You just read:

SillaJen Announces Collaboration with the National Cancer Institute for Development of Combination Therapy with SillaJen's pexastimogene devacirepvec (Pexa-Vec) Oncolytic Immunotherapy

News provided by

SillaJen, Inc.

Aug 16, 2017, 19:30 ET